


REMARKS

Claims 2 and 4-9 are amended and claims 1 and 3 are cancelled. Claims 2, 4-9 and 10-18 are presented for examination. These amendments are made prior to examination without limiting the scope of the claims as first written. These amendments are not made for reasons of patentability under 35 U.S.C. 101, 102, 103 or 112 and no estoppel is created hereby.

It is believed that claims 2, 4-9 and 10-18 recite a patentable improvement in the art. Favorable action is solicited. In the event any fees are required with this paper, please charge our Deposit Account No. 02-2334.

Respectfully submitted,



William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Attorney Docket No. 99473 US
Akzo Nobel Patent Department
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850-4373
Tel: (301) 948-7400
Fax: (301) 948-9751

WMB:lcf-
101COELINGH-BENNINK-PREAMENDMENT

VERSION WITH MARKINGS TO SHOW CHANGES MADE

2. (Amended) [A use] The method according to [claim 1, characterised in that] claim 11, wherein the intermittent administration of Org 33245 takes place as an addition to progestagen-only therapy.

4. (Amended) [A use according to any of the preceding claims, characterised in that a dosage of] The method of claim 11, wherein Org 33245 is [to be] administered for 1-7 days during a cycle of 28-32 days, wherein one dosage marks the end of a cycle and the optional other dosages [to be] are administered regularly divided over the remaining days of the cycle.

5. (Amended) A contraceptive kit [providing means (a)] for the daily administration of a progestagen and [means (b)] for the intermittent administration of an anti-progestagen, [wherein the latter means (b) comprises as the anti-progestagen the compound] comprising a progestagen dosage unit and an anti-progestagen dosage unit, wherein the anti-progestagen dosage unit comprises Org 33245 [as defined in the description].

6. (Amended) A combined [means for the] dosage unit [of] comprising a progestagen and an anti-progestagen, [characterised in that] wherein the anti-progestagen is Org 33245 [as defined in the description].

7. (Amended) A method of contraception comprising daily administering to a female of childbearing age a contraceptively effective amount of a progestagen and intermittently administering an anti-progestagen, wherein the anti-progestagen is Org 33245 [as defined in the description].

8. (Amended) A method of treatment of irregular or breakthrough uterine bleeding in a female using a progestagen-only preparation, comprising intermittently administering an

anti-progestagen, wherein the anti-progestagen is Org 33245 [as defined in the description].

9. (Amended) [A] The method according to claim 7 [or 8], wherein the anti-progestagen is administered on 1-4 days in a cycle of 28-32 days.